University of Texas M. D. Anderson Cancer Center researchers have identified tissue type transglutaminase (TG2) as potential therapeutic target in chemotherapy-resistant ovarian cancer.
“….found overexpression of tissue type transglutaminase (TG2) in ovarian cancer is associated with increased tumor cell growth and adhesion, resistance to chemotherapy and lower overall survival rates.
When researchers targeted and silenced TG2 in animal models, cancer progression was reversed, suggesting the protein may also provide a novel therapeutic approach for late-stage ovarian cancer.”
Reported findings appear in the July 15th issue of Cancer Research.
Read more from UT MD Anderson Cancer Center.